We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.5 | 15.015015015 | 3.33 | 3.88 | 3.06 | 116436 | 3.28698908 | CS |
4 | -0.93 | -19.5378151261 | 4.76 | 5.13 | 3.06 | 141608 | 3.75663617 | CS |
12 | -5.56 | -59.2119275825 | 9.39 | 9.789 | 3.06 | 135840 | 5.77816376 | CS |
26 | -12.95 | -77.1752085816 | 16.78 | 18.01 | 3.06 | 128504 | 9.07002581 | CS |
52 | -21.46 | -84.8556741795 | 25.29 | 40.98 | 3.06 | 132164 | 16.81067383 | CS |
156 | -2.17 | -36.1666666667 | 6 | 40.98 | 3.06 | 130847 | 17.57631736 | CS |
260 | -2.17 | -36.1666666667 | 6 | 40.98 | 3.06 | 130847 | 17.57631736 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions